Please use this identifier to cite or link to this item:
Title: Effect of Gender on the Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093), a New Voltage-gated Sodium Channel Blocker
Authors: Falcão, Amílcar 
Maia, Joana 
Almeida, Luís 
Mazur, Dago 
Gellert, Manfred 
Soares-da-Silva, Patrício 
Keywords: eslicarbazepine acetate; gender effects; pharmacokinetics
Issue Date: 2007
Publisher: Wiley InterScience
Citation: Falcão, Amílcar et al - Effect of Gender on the Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093), a New Voltage-gated Sodium Channel Blocker. Biopharm Drug Dispos 28 (2007) 249–256
Abstract: Purpose. To determine the effect of gender on the pharmacokinetics of eslicarbazepine acetate, a novel voltage-gated sodium channel blocker in the development for the treatment of epilepsy and bipolar disorder. Methods. Single-centre, open-label, parallel-group study in 12 female and 12 male healthy subjects. The study consisted of a single-dose (600 mg) period and a multiple-dose (600 mg, oncedaily, for 8 days) period, separated by 4 days. Results. Eslicarbazepine acetate was rapidly and extensively metabolized to eslicarbazepine (S-licarbazepine), the main active metabolite. Following a single-dose, arithmetic mean eslicarbazepine maximum plasma concentrations (Cmax) and area under the plasma concentration-time curve over 24 h (AUC0 24) and from 0 to infinity (AUC0 1) were, respectively, 9.3 mg/ml, 128.5 mg h/ml and 171.9 mg h/ml in male subjects and 10.1 mg/ml, 150.1 mg h/ml and 205.0 mg h/ml in female subjects. At steady-state, Cmax, AUC0 24 and AUC0 1 were 15.5 mg/ml, 207.8 mg h/ml and 295.8 mg h/ml in male subjects, and 16.8 mg/ml, 214.5 mg h/ml and 295.2 mg h/ml in female subjects. Steady-state plasma concentrations were attained at 4 to 5 days of administration in both groups. Eslicarbazepine Cmax, AUC0 24 and AUC0 1 female:male geometric mean ratios (90%CI) were, respectively, 1.09 (0.94; 1.24), 1.16 (1.00; 1.33) and 1.17 (0.99; 1.38) following single-dose, and 1.10 (0.97; 1.25), 1.04 (0.92; 1.17) and 1.01 (0.88; 1.16) at steady-state. Conclusion. At steady-state, the pharmacokinetic profile of eslicarbazepine acetate was not affected by gender.
DOI: 10.1002/bdd.549
Rights: openAccess
Appears in Collections:FFUC- Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
Falcao 2007 - Eslicarbazepine Gender Effect Biopharmaceutics & Drug Disposition.pdf128.91 kBAdobe PDFView/Open
Show full item record


checked on Aug 2, 2022

Page view(s) 20

checked on Aug 4, 2022

Download(s) 50

checked on Aug 4, 2022

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.